QIAGEN Acquires Point-of-Need Assay
The acquisition adds to QIAGEN’s capabilities for OB/GYN sales and to its line of point-of-need tests, which include lateral flow reader and tube scanner product lines. QIAGEN also holds a minority stake in EyeSense, which is developing a point of-need blood glucose–monitoring device (see IBO 4/15/11).
Hilden, Germany and Germantown, Maryland 5/3/12—QIAGEN has acquired AmniSure International for an undisclosed amount. AmniSure International markets the FDA-approved, point-of-need AmniSure assay, which tests if a pregnant woman has suffered a rupture of fetal membranes (ROM). “This very accurate diagnostic test contributes significant value in the management of pregnancy and adds to QIAGEN’s portfolio of tests and in particular for the OB/GYN market that also includes our gold-standard digene HPV Test,” said QIAGEN CEO Peer Schatz. “Our clinical sales force in the US, which primarily serves the OB/GYN market, offers significant synergies to drive adoption of AmniSure, so the transaction also adds momentum to our strategic initiative to grow efficiently and effectively.” The acquisition is expected to contribute $12 million to QIAGEN sales for the remainder of this year and sales of $24 million in 2013. The acquisition is expected to be neutral to adjusted EPS in 2012 and to be accretive by $0.02 in 2013. QIAGEN stated that as many as 30% of women are checked for ROM in clinical settings.
